Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling

Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07158086

Acronym

BIOCARDIUM-HF

Enrollment

500

Registered

2025-09-05

Start date

2025-11-01

Completion date

2031-11-30

Last updated

2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure (for Example, Fluid Overload)

Brief summary

The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients. The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Female and Male, age ≥18 years at screening. * Diagnosis of Heart Failure according to ESC Heart Failure Guidelines * Ability to understand the requirements of the study and to provide informed consent. * Willingness to undergo follow-up.

Exclusion criteria

Patients will be excluded if they meet any of the following conditions: * Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy). * Autoimmune or systemic inflammatory diseases. * Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases). Other

Design outcomes

Primary

Measure	Time frame
Death from any cause	From enrollment up to five years
Heart failure hospitalization	From enrollment up to five years

Countries

Switzerland

Contacts

Primary ContactJan A Kleeberger, MD

janalphard.kleeberger@usz.ch+41763220376

Outcome results